Trial Profile
The clinical trial of G-CSF combine with low-dose dicitabine in the prophylaxis of high risk acute myeloid leukemia relapse after allogenetic hematopoietic stem cell transplantation
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results (n=19, data cut off: Jun 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 14 Oct 2018 Planned number of patients changed from 242 to 120.
- 28 Apr 2016 New trial record